A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

作者：Fehniger Todd A^*; Larson Sarah; Trinkaus Kathryn; Siegel Marilyn J; Cashen Amanda F; Blum Kristie A; Fenske Timothy S; Hurd David D; Goy Andre; Schneider Stephanie E; Keppel Catherine R; Wagner Johnston Nina D; Carson Kenneth R; Bartlett Nancy L

来源：Blood, 2011, 118(19): 5119-5125.

DOI：10.1182/blood-2011-07-362475

Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg/d on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event (AE) occurred. Thirty-eight cHL patients were enrolled with a median of 4 (range, 2-9) prior therapies; 87% had undergone prior stem cell transplantation and 55% of patients did not respond to their last prior therapy. Of 36 evaluable patients, responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable disease (SD) for >= 6 months resulting in an International Working Committee (IWC) objective overall response rate (ORR) of 19% and a cytostatic ORR of 33%. Decreased chemokine (CCL17 and CCL22) plasma levels at 2 weeks were associated with a subsequent response. The treatment was well tolerated, and the most common grade 3/4 AEs were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide because of rash, elevated transaminases/bilirubin, and cytopenias. We provide preliminary evidence of lenalidomide's activity in patients with rel/ref cHL, and therefore exploration of lenalidomide in combination with other active agents is warranted. This trial is registered at www.ClinicalTrials.gov as NCT00540007. (Blood. 2011;118(19):5119-5125)

• 出版日期2011-11-10